Events and training - April 22, 2024
Earth Day 2024: Our planet prefers TIVA anaesthesia—do you?
Healthcare’s climate footprint is equivalent to 4.4% of global net emissions; this means that if the health sector were a…
Earth Day 2024: Our planet prefers TIVA anaesthesia—do you?
Healthcare’s climate footprint is equivalent to 4.4% of global net emissions; this means that if the health sector were a…
Reducing infection with catheter care bundles
Catheter-related bloodstream infections (CRBSIs) are a serious threat to patients with a vascular access device, yet many are preventable using…
“Complications of IV catheter therapy are simply the result of one complex and highly variable mechanical system—IV catheter equipment design,...
BD IV News 2.0: building an IV therapy community
Your source of information on IV therapy just got a whole lot better. Following feedback from readers, BD IV News…
Device and drug shortages in Europe persist, new survey shows
Countries across the globe face a wide range of challenges in accessing necessary health products, such as shortages and stockouts.1…
Scientific evidence on VATs: Is there enough? Is it robust?
There is much scientific evidence available on the efficacy of vascular access teams (VATs) in managing costs, preventing intravenous (IV)…
How to turn a PICC team into a vascular access team
On the second day of BD MACOV@23, a virtual edition of the Multidisciplinary Advanced Course on Vascular Access (MACOVA) held…
Best practices for phase 1 investigational drugs trials
Before pharmaceutical products are released onto the market, they undergo extensive screening as an investigational drug (IND, or investigational new…
Fast fact
Propofol-based total intravenous anaesthesia (TIVA) emits four orders of magnitude less greenhouse gases than inhaled anaesthesia with desflurane and N2O.